Navigation Links
Jefferson awarded multi-million dollar grant from National Eye Institute for new clinical trial
Date:10/1/2008

PHILADELPHIA Researchers at the Farber Institute for Neurosciences at Thomas Jefferson University and the Department of Psychiatry and Human Behavior at Jefferson Medical College of Thomas Jefferson University were recently awarded a $3.7 million grant from The National Eye Institute to study depression in patients diagnosed with age-related macular degeneration (AMD). Barry W. Rovner, M.D., director of Clinical Alzheimer's Disease Research at the Farber Institute for Neurosciences and professor of Psychiatry and Neurology at Jefferson Medical College; and Robin Casten, Ph.D., associate professor of Psychiatry and Human Behavior at Jefferson Medical College, will lead the single site study of 200 AMD patients, who will be followed for 12 months, to determine the effectiveness of a treatment program designed to prevent depression and disability in these patients.

AMD is the leading cause of vision loss in Americans 60 years of age and older. It gradually destroys sharp, central vision, which is needed for seeing objects clearly and for common daily tasks such as reading and driving. AMD affects the macula, the part of the eye that allows you to see fine detail. In some cases, the disease advances so slowly that people notice little change in their vision. In others, it progresses faster and may lead to a loss of vision in both eyes.

"Vision loss in the elderly is a major risk factor for depression. The disease robs older persons of their ability to perform everyday activities and limits their independence," said Dr. Rovner. "The loss of these abilities and having to give up valued activities can lead to depression. We want to find ways to improve the vision skills of people with AMD and thereby prevent depression."

The Low Vision Depression Prevention Trial will test a combined treatment to prevent depression and disability associated with AMD. It will test the efficacy of a low vision rehabilitation and psychological intervention program designed to treat/prevent depression in patients diagnosed with the disease by helping them maintain their independence and participation in enjoyable activities. The study consists of two low vision optometry visits, in which specially trained optometrists will evaluate visual function and develop a rehabilitative plan; and six in-home occupational therapy visits where low-vision occupational therapists will teach compensatory strategies to improve visual ability and administer a behavioral treatment to activate subjects and enable them to remain engaged in valued activities.

"Vision loss in the elderly is extremely distressing, significantly impacts quality of life, and is a risk factor for nursing home placement," said Dr. Casten. "Finding ways to help these patients maintain their independence and engagement with life is key to promoting successful aging."


'/>"/>

Contact: Ed Federico
ed.federico@jefferson.edu
Thomas Jefferson University
Source:Eurekalert

Related medicine news :

1. Thomas Jefferson University to Host Summit With National Experts to Discuss A New Age in Dementia Care
2. Jefferson researchers show antibody to breast cancer-secreted protein blocks metastasis
3. East Jefferson General Hospital Selects Allscripts Electronic Health Record, Offers Free Electronic Prescribing for Affiliated New Orleans-Area Physicians
4. Different type of colon cancer vaccine reduces disease spread, Jefferson scientists show
5. Blocking signaling protein prevents prostate cancer spread, Jefferson scientists find
6. Jefferson, Ohio State team find gene signature profile for metastasis
7. Monitoring blood flow helps improve prostate biopsies, Jefferson researchers report
8. Traditional herbal medicine kills pancreatic cancer cells, Jefferson researchers report
9. Independence Blue Cross, Jefferson Health System Reach Agreement on New Three-Year Contracts
10. Blood pressure drugs halt pancreatic cancer cell growth, Jefferson researchers find
11. Jefferson scientists discovery may help explain smoking-pancreatic cancer link
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 23, 2017 , ... The TouchPoint Solution, ... who entered metrics into the product’s app. The data replicates and validates ... that within just 30 seconds of using Buzzies, people experienced a 74 percent ...
(Date:1/24/2017)... Michigan (PRWEB) , ... January 24, 2017 , ... The ... other advocates for drug and alcohol awareness, have worked with communities to designate the ... year, observed January 23-29, 2017, the theme is “Shatter the Myths.” As a ...
(Date:1/23/2017)... ... January 23, 2017 , ... ... localization services for life science companies, has achieved ISO 17100:2015 certification following ... America. ISO 17100 is the globally recognized standard that establishes guidance for ...
(Date:1/23/2017)... ... 23, 2017 , ... The iaedp Foundation, recognized for its ... who treat the full spectrum of eating disorder problems, proudly announces the addition ... of the leading eating disorder treatments centers located throughout the U.S. As partners ...
(Date:1/23/2017)... ... 2017 , ... Sharon Kleyne, America’s leading water researcher, advocate and feared enemy ... of making new water infrastructure a number one priority. “As we usher in a ... infrastructure to become a top priority of our new political change agents.” Kleyne pointed ...
Breaking Medicine News(10 mins):
(Date:1/24/2017)... 23, 2017 ArisGlobal, a leading ... announces agClinical 3.3, the latest version of its comprehensive ... science organizations to confidently and efficiently meet new compliance ... the electronic trial master file so that compliance is ... ...
(Date:1/23/2017)... 2017  HOPE BIOSCIENCES announced today that it ... commercialize nuc -gemcitabine™ (APTA-12/HOPE-888) through a licensing ... nuc -Gemcitabine consists of Antisoma,s ... found on many cancer cells, and dFdCMP, an ... conjugates) or SMDCs (small molecule drug conjugates), which ...
(Date:1/23/2017)... 23, 2017  Therabron Therapeutics, Inc., a clinical-stage ... in respiratory care, today announced that the European ... has granted Orphan Drug Designation for Therabron,s CG367 ... Syndrome (BOS).  "We are pleased to ... to treat patients diagnosed with BOS following lung ...
Breaking Medicine Technology: